Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
AUSTIN, Texas - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has recently announced the publication of two new studies in Nature Medicine that evaluate the clinical utility of their personalized and tumor-informed molecular residual disease (MRD) test, Signatera. These studies showcase the potential benefits of Signatera in patients with gastrointestinal malignancies.
The first study, called the AMPLIFY-201 trial, focused on assessing the efficacy of the ELI-002 cancer vaccine. This single-arm, phase I study enrolled a total of 25 patients, 20 of whom had pancreatic cancer and 5 with colorectal cancer. Out of these patients, 21 were Signatera-positive, indicating the presence of residual disease. The results of this study highlight the potential of Signatera in guiding treatment decisions and monitoring response to therapy in gastrointestinal malignancies.
In another study, published in Molecular Oncology, Natera compared the performance of two different methods, mean tumor molecules per milliliter (MTM/mL) and mean variant allele frequency (mVAF), for measuring circulating tumor DNA (ctDNA) using Signatera. The study aimed to determine the most accurate method for quantifying ctDNA levels. Given that ctDNA is a promising biomarker for cancer detection and monitoring, finding the optimal method for its quantification is of utmost importance. The study results will provide valuable insights into the use of Signatera for MRD assessment and ctDNA quantification.
Furthermore, Natera’s RenaCARE study, published in the Journal of the American Society of Nephrology, demonstrated the diagnostic and clinical utility of Renasight in chronic kidney disease (CKD) patients. RenaCARE is a large-scale, prospective study that assessed the impact of genetic testing in the CKD population. The study enrolled 1,623 patients across various community and academic sites. The initial results of the study indicate the potential of Renasight in improving diagnostic accuracy and guiding personalized treatment strategies for CKD patients.
These publications highlight Natera’s commitment to advancing the field of personalized medicine through innovative and accurate molecular diagnostics. The studies provide evidence of the clinical utility of Signatera in the management of gastrointestinal malignancies and chronic kidney disease. By providing reliable information about residual disease and ctDNA levels, Signatera has the potential to transform treatment decision-making and improve patient outcomes.
In summary, Natera’s recent publications in renowned scientific journals like Nature Medicine and the Journal of the American Society of Nephrology signify significant advancements in the field of molecular diagnostics. The studies provide valuable insights into the potential of Signatera and Renasight in improving patient care and contribute to the growing body of evidence supporting the clinical utility of these tests.
Comments